Optimal antithyroid medication dosage reduction for patients with moderate to severe Graves' disease
Not Applicable
- Conditions
- Graves'disease
- Registration Number
- JPRN-UMIN000052937
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with untreated Graves' disease who plan to attend a facility participating in this study will be included. (1) Pregnant women, lactating women, and patients who plan to become pregnant within 2 years (2) Patients with untreated Graves' disease who may have thyroid crisis (3) Patients who have received curative treatment for Graves' disease (surgery, intra-iodine radioiodine therapy) in the past (4) Patients receiving immunosuppressive therapy or drugs that affect thyroid function (amiodarone, lithium carbonate, immune checkpoint drugs) (5) Other patients deemed inappropriate as research subjects by the principal investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method